TY - JOUR
T1 - High response rate to cisplatin/etoposide regimen in childhood low-grade glioma
AU - Massimino, Maura
AU - Spreafico, Filippo
AU - Cefalo, Graziella
AU - Riccardi, Riccardo
AU - Tesoro-Tess, John David
AU - Gandola, Lorenza
AU - Riva, Daria
AU - Ruggiero, Antonio
AU - Valentini, Laura
AU - Mazza, Elena
AU - Genitori, Lorenzo
AU - Di Rocco, Concezio
AU - Navarria, Piera
AU - Casanova, Michela
AU - Ferrari, Andrea
AU - Luksch, Roberto
AU - Terenziani, Monica
AU - Balestrini, Maria Rosa
AU - Colosimo, Cesare
AU - Fossati-Bellani, Franca
PY - 2002/10/15
Y1 - 2002/10/15
N2 - Purpose: The aim of this study was to avoid radiotherapy and to induce an objective response in children with low-grade glioma (LGG) using a simple chemotherapy regimen based on cisplatin and etoposide. Patients and Methods: Thirty-four children (median age, 45 months) with unresectable LGG were treated with 10 monthly cycles of cisplatin (30 mg/m2/d on days 1 to 3) and etoposide (150 mg/m2/d on days 1 to 3). Tumor originated in the visual pathway in 29 patients, in the temporal lobe in two, in the frontal lobe in two, and in the spine in one. Eight children were affected by neurofibromatosis type 1. Objective tumor response and toxicity were evaluated by magnetic resonance imaging and neurologic and functional tests at 3-month intervals. Results: An objective response was obtained in 24 (70%) of 34 patients, whereas the others had stable disease. None of the children were electively irradiated. In 31 previously untreated children, overall survival was 100% and progression-free survival was 78% at 3 years, with a median follow-up of 44 months. Acute toxicity was unremarkable; 28% patients evaluated for acoustic neurotoxicity revealed a loss of perception of high frequencies. Conclusion: Cisplatin and etoposide combined treatment is one of the most active regimens for LGG in children and allows avoidance of radiotherapy in the vast majority of patients.
AB - Purpose: The aim of this study was to avoid radiotherapy and to induce an objective response in children with low-grade glioma (LGG) using a simple chemotherapy regimen based on cisplatin and etoposide. Patients and Methods: Thirty-four children (median age, 45 months) with unresectable LGG were treated with 10 monthly cycles of cisplatin (30 mg/m2/d on days 1 to 3) and etoposide (150 mg/m2/d on days 1 to 3). Tumor originated in the visual pathway in 29 patients, in the temporal lobe in two, in the frontal lobe in two, and in the spine in one. Eight children were affected by neurofibromatosis type 1. Objective tumor response and toxicity were evaluated by magnetic resonance imaging and neurologic and functional tests at 3-month intervals. Results: An objective response was obtained in 24 (70%) of 34 patients, whereas the others had stable disease. None of the children were electively irradiated. In 31 previously untreated children, overall survival was 100% and progression-free survival was 78% at 3 years, with a median follow-up of 44 months. Acute toxicity was unremarkable; 28% patients evaluated for acoustic neurotoxicity revealed a loss of perception of high frequencies. Conclusion: Cisplatin and etoposide combined treatment is one of the most active regimens for LGG in children and allows avoidance of radiotherapy in the vast majority of patients.
UR - http://www.scopus.com/inward/record.url?scp=0037108821&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037108821&partnerID=8YFLogxK
U2 - 10.1200/JCO.2002.08.087
DO - 10.1200/JCO.2002.08.087
M3 - Article
C2 - 12377964
AN - SCOPUS:0037108821
VL - 20
SP - 4209
EP - 4216
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
SN - 0732-183X
IS - 20
ER -